Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-10 09:43 am Unchanged | 2022-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR | Flynn James E | 0 0.000% | 0 (Unchanged) | Filing History |
| 2022-11-09 4:43 pm Sale | 2022-10-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR | BlackRock Inc. BLK | 0 0.000% | -900,132 (Position Closed) | Filing |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCRU | T. Rowe Price Associates, Inc. | 730,864 5.400% | 730,864 (New Position) | Filing History |
| 2022-02-08 5:12 pm Sale | 2021-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR | BlackRock Inc. BLK | 900,132 6.700% | -24,868 (-2.69%) | Filing |
| 2021-02-12 4:02 pm Purchase | 2020-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR | Eucrates LLC | 2,619,906 19.500% | 2,619,906 (New Position) | Filing History |
| 2021-02-05 5:51 pm Purchase | 2020-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR | BlackRock Inc. BLK | 925,000 6.900% | 925,000 (New Position) | Filing |
| 2020-10-30 11:39 am Purchase | 2020-10-27 | 13G | Eucrates Biomedical Acquisition Corp. EUCRU | Flynn James E | 1,000,000 7.780% | 1,000,000 (New Position) | Filing History |